United Therapeutics Corporation  (UTHR)
Other Ticker:  
Price: $225.6400 $-1.64 -0.722%
Day's High: $228.59 Week Perf: -0.61 %
Day's Low: $ 223.52 30 Day Perf: 4.94 %
Volume (M): 766 52 Wk High: $ 261.54
Volume (M$): $ 172,863 52 Wk Avg: $225.92
Open: $228.59 52 Wk Low: $204.44

 Market Capitalization (Millions $) 11,217
 Shares Outstanding (Millions) 50
 Employees 1,044
 Revenues (TTM) (Millions $) 2,328
 Net Income (TTM) (Millions $) 985
 Cash Flow (TTM) (Millions $) 247
 Capital Exp. (TTM) (Millions $) 230

United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company headquartered in Silver Spring, Maryland. The company is focused on the development, manufacturing, and commercialization of innovative therapies to treat rare disorders and life-threatening diseases. It was founded in 1996 by Martine Rothblatt.

The company has a diverse portfolio of products that includes both therapeutic drugs and wearable technology for remote patient monitoring. It conducts extensive research in pulmonary hypertension (PH), neuroblastoma, and hematologic cancers.

United Therapeutics operates in several business segments: commercial, research and development, and manufacturing. The company has a strong global presence and has offices and facilities in the United States, Europe, and Asia.

One of the key drugs developed by United Therapeutics is called Remodulin, which is used to treat pulmonary arterial hypertension (PAH). PAH is a rare and life-threatening condition that occurs when the blood vessels in the lungs become narrow, leading to high blood pressure and eventual heart failure. Remodulin is administered through a small pump that is connected to a catheter in the patientes chest.

Another drug developed by United Therapeutics is called Tyvaso, which is also used to treat PAH. Tyvaso is an inhaled medication that is delivered through a portable device.

In addition to developing therapies for PAH, United Therapeutics is actively researching treatments for neuroblastoma, a rare cancer that affects children, as well as hematologic cancers such as leukemia and lymphoma.

The company also offers wearable technology for remote patient monitoring. One of the most notable products is the TytoCare device, which allows patients to perform basic medical exams at home and share the data with their healthcare providers.

United Therapeutics has received numerous accolades for its contributions to the biotech industry. In 2017, the company was recognized as one of the worldes most innovative companies by Forbes magazine.

Overall, United Therapeutics Corporation is dedicated to improving the lives of patients with rare and life-threatening diseases through innovative research, manufacturing, and commercialization of high-quality therapies and medical devices.

   Company Address: 1000 Spring Street, Silver Spring, 20910 MD
   Company Phone Number: 608-9292   Stock Exchange / Ticker: NASDAQ UTHR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

United Therapeutics Corporation

United Therapeutics Corporation Rises Above the Sinking Major Pharmaceutical Preparations Industry, Achieving Spectacular Revenue Surge and Steady Profitability Growth in Q3 2023.

United Therapeutics Corporation has emerged as a shining star in the third quarter of 2023, standing tall amidst a struggling Major Pharmaceutical Preparations sector. With a remarkable double-digit revenue advance of 18.101% to $609.40 million, the company has showcased its resilience and ability to navigate through challenging times.
In addition to the impressive revenue growth, United Therapeutics Corporation also experienced a modest profitability advance of 9.57% to $5.38 per share. This exceptional performance not only demonstrates the company's strong financial footing but also showcases its ability to generate consistent profits.

United Therapeutics Corporation

United Therapeutics Corporation Witnesses Remarkable Revenue Surge in Recent Fiscal Period, Outperforms Pharmaceutical Industry Peers

United Therapeutics Corporation has showcased impressive financial results in its most recent fiscal period, with a significant increase in both earnings per share and revenue. Earnings per share more than doubled by 117.43% year on year, reaching $5.24 per share, while revenue grew by 27.758% to $596.50 million. This performance has surpassed that of its industry peers, as the Major Pharmaceutical Preparations industry only experienced a 3.96% top-line advance during the same period.
The company's sequential income also improved by 7.82% from $4.86 per share, and revenue increased by 17.676% from $506.90 million. Such growth is evident in the net profits that soared to $259.200 million in the April to June 30, 2023 fiscal interval, a staggering 123.45% increase compared to the same period a year ago when net earnings reached $116.000 million.

United Therapeutics Corporation

United Therapeutics Corporation Beats Expectations with Impressive Revenue Growth Despite Decreased Profitability

United Therapeutics Corporation, a leading biotechnology company focused on the development of innovative therapies for life-threatening diseases, has recently reported its financial results for the January to March 31 2023 period, and it's time for investors to get bullish.
Even though the company encountered a 3.38% decrease in earnings per share (EPS) compared to the prior year quarter, it's important to consider the bigger picture. After all, United Therapeutics Corporation managed to expand its sales, which is always great news for any business looking to grow. Revenue increased by an impressive 9.742% to $506.90 million in comparison to $461.90 million in the prior year quarter, which shows that the company is making strides towards its goal of becoming a dominant player in the biotechnology industry.


United Therapeutics's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
United Therapeutics does not provide revenue guidance.

Earnings Outlook
United Therapeutics Corporation does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com